168 related articles for article (PubMed ID: 35451147)
1. Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: Experience from clinical practice of four tertiary hospitals.
Tampouratzi E; Papakonstantis M; Katsantonis J; Sidiropoulos T; Delli F; Efthymiadis K; Sfaelos K; Christodoulou A; Chasapi V; Panagakis P
Dermatol Ther; 2022 Jul; 35(7):e15532. PubMed ID: 35451147
[TBL] [Abstract][Full Text] [Related]
2. Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study.
Rigopoulos D; Angelakopoulos C; Apalla Z; Georgiou S; Delli F; Drosos A; Zafiriou E; Katsantonis J; Lazaridou E; Panagakis P; Papadavid E; Papakonstantis M; Roussaki-Schulze AV; Sotiriou E; Anastasiadis G; Tampouratzi E; Chasapi V; Sfaelos K; Ioannides D;
Dermatol Ther; 2022 Dec; 35(12):e15886. PubMed ID: 36184757
[TBL] [Abstract][Full Text] [Related]
3. Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece.
Papadavid E; Zafeiriou E; Georgiou S; Roussaki-Schulze AV; Spiliopoulos T; Vryzaki E; Oikonomou C; Drongoula O; Boziou M; Goudouras G; Sfaelos K; Apalla Z; Lazaridou E
J Dermatolog Treat; 2022 Nov; 33(7):3053-3059. PubMed ID: 36000186
[TBL] [Abstract][Full Text] [Related]
4. Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).
Rigopoulos D; Tampouratzi E; Angelakopoulos C; Apalla Z; Barkis I; Georgiou S; Delli F; Drosos A; Zafiriou E; Katsantonis J; Lazaridou E; Panagakis P; Papadavid E; Papakonstantis M; Roussaki-Schulze AV; Sotiriou E; Anastasiadis G; Chasapi V; Sfaelos K; Ioannides D;
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):1121-1130. PubMed ID: 38308561
[TBL] [Abstract][Full Text] [Related]
5. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
6. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting.
Megna M; Potestio L; Camela E; Fabbrocini G; Ruggiero A
Dermatol Ther; 2022 Sep; 35(9):e15667. PubMed ID: 35762107
[TBL] [Abstract][Full Text] [Related]
7. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
Lebwohl MG; Blauvelt A; Menter A; Papp KA; Guenthner S; Pillai R; Israel RJ; Jacobson A
Am J Clin Dermatol; 2019 Dec; 20(6):863-871. PubMed ID: 31493163
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: The ProLOGUE study.
Imafuku S; Ohata C; Okubo Y; Tobita R; Saeki H; Mabuchi T; Hashimoto Y; Murotani K; Kitabayashi H; Kanai Y
J Dermatol Sci; 2022 Mar; 105(3):176-184. PubMed ID: 35248465
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of ustekinumab for moderate-to-severe psoriasis: A 9-year real-life experience from a tertiary referral center in Turkey.
Babuna Kobaner G; Polat Ekinci A; Kutlay A
Dermatol Ther; 2021 Jul; 34(4):e15042. PubMed ID: 34161621
[TBL] [Abstract][Full Text] [Related]
11. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience.
Fargnoli MC; Esposito M; Dapavo P; Parodi A; Rossi M; Tiberio R; Dastoli S; Offidani AM; Argenziano G; Gisondi P; Lo Schiavo A; Loconsole F; Pella P; Bardazzi F; Cusano F; Gattoni M; Nacca M; Cannavò SP; Pellegrini C; Costanzo A;
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):693-700. PubMed ID: 32916767
[TBL] [Abstract][Full Text] [Related]
12. Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain.
Galan-Gutierrez M; Font-Ugalde P; Padilla L; Hernandez-Montoya C; Godoy D; Armario-Hita JC; Ruiz-Villaverde R
Int J Dermatol; 2023 May; 62(5):700-706. PubMed ID: 36495585
[TBL] [Abstract][Full Text] [Related]
13. Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch.
Gaudet V; Yap B; Hassan S; Barbeau M
J Cutan Med Surg; 2023; 27(3):226-235. PubMed ID: 37083148
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
Seo SJ; Shin BS; Lee JH; Jeong H
J Dermatol; 2021 Jun; 48(6):807-817. PubMed ID: 33373480
[TBL] [Abstract][Full Text] [Related]
15. A Real-Life 208 Week Single-Centred, Register-Based Retrospective Study Assessing Secukinumab Survival and Long-Term Efficacy and Safety Among Greek Patients with Moderate to Severe Plaque Psoriasis, Including Difficult-to-Treat Manifestations Such as Genitals and Scalp.
Kyrmanidou E; Kemanetzi C; Stavros C; Trakatelli MG; Patsatsi A; Madia X; Ignatiadi D; Kalloniati E; Apalla Z; Lazaridou E
Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38810083
[TBL] [Abstract][Full Text] [Related]
16. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy.
Galluzzo M; Caldarola G; De Simone C; Bernardini N; Moretta G; Pallotta S; Botti E; Campione E; Pirro F; Potenza C; Bianchi L; Peris K
Expert Opin Biol Ther; 2021 Sep; 21(9):1299-1310. PubMed ID: 34114515
[No Abstract] [Full Text] [Related]
17. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3.
Warren RB; Hansen JB; Reich K; Paul C; Puig L
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):450-457. PubMed ID: 32662540
[TBL] [Abstract][Full Text] [Related]
18. Ixekizumab for treatment of moderate to severe plaque psoriasis: real world clinical experience.
Diotallevi F; Campanati A; Radi G; Molinelli E; Offidani A
G Ital Dermatol Venereol; 2020 Dec; 155(6):739-743. PubMed ID: 30428651
[TBL] [Abstract][Full Text] [Related]
19. Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks.
Rompoti N; Politou M; Stefanaki I; Vavouli C; Papoutsaki M; Neofotistou A; Rigopoulos D; Stratigos A; Nicolaidou E
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):689-697. PubMed ID: 36562663
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real-world, single-center experience.
Radi G; Campanati A; Diotallevi F; Rizzetto G; Martina E; Bobyr I; Giannoni M; Offidani A
Dermatol Ther; 2021 Nov; 34(6):e15179. PubMed ID: 34704350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
